BioSpace News Archive

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, has reported full 2-year clinical results from its ARTISAN-SNM pivotal study.

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in H.C. Wainwright & Co., 22 nd Annual Investment Conference being held virtually September 14-16 2020. ProMIS’ Executive Chairman, Eugene Williams, will provide

- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), a veterinary health company creating point-of-care diagnostics products for companion animals, announced today that Robert Cohen, Interim Chief Executive Officer, and Stephanie Morley, President and Chief Medical Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference. The presentation is scheduled for September 14, 2020 at 4:00 pm ET. The slides to be p

Selvita (WSE: SLV), one of the largest preclinical contract research organizations in Europe , reported today its H1 2020 financial results and provided a corporate update. For the H1 2020, Selvita reports consolidated revenues of EUR 15.2 million , up by 47% on a year-on-year basis. The EBITDA result reached EUR 3.6 mil

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that Michael F. Cola, President and Chief Executive Officer, will present at two upcoming virtual conferences. H.C. Wainwright 22nd Annual Global Investment Conference Date: Monday, September 14, 2020 Time: 3:00 PM ET Oppenheimer Fall Heal

Enspryng was recently approved by the U.S. Food and Drug Administration (FDA) for adults with anti-aquaporin-4 (AQP4) antibody positive NMOSD

Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Trogarzo® will be commercially available in Germany as of tomorrow through its subsidiary, Theratechnologies Europe Limited.

Chugai Pharmaceutical Co., Ltd. announced the presentation of new Enspryng® data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder, a rare disease of the central nervous system.

ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced its presentation at the H.C. Wainwright 22nd Annual Global Investment Conference.

Transparency Market Research has published a new report titled, ‘Medical Waste Containers Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.